Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

NCT04701502 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
Respiratory Disease
Immune System
Immunomodulator
Antiseptic
Supportive Care

Interventions

DIETARY_SUPPLEMENT: Viusid
DIETARY_SUPPLEMENT: Asbrip
DRUG: Standard Care

Sponsor

Catalysis SL